[{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Zhejiang Sunshine Mandi Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Minoxidil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Alopecia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 23, 2025

                          Lead Product(s) : Minoxidil

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Clascoterone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acne Vulgaris.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 12, 2024

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Clascoterone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 08, 2024

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank